On January 12, 2026 Oricell Therapeutics Holdings Limited ("Oricell" or "the Company"), a global leader in innovative cancer immunotherapy, reported the closing of a $70M Series C1 financing.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The round was co-led by Beijing Medical and Health Care Industry Investment Fund, Qiming Venture Partners and a leading global healthcare fund, with participation from a sovereign wealth fund, NGS Super (NGS), E-Town Capital, Elikon Venture, and Talon Capital. Proceeds will accelerate Oricell’s global expansion and clinical development, while strengthening its technological capabilities and paving ways to commercialization.

Oricell is advancing a differentiated pipeline of CAR-T cell therapies for solid tumors, underpinned by three proprietary platforms developed over the past decade:

OriAb: antibody discovery and engineering library
OriArmoring: enhancement of T-cell persistence and other crucial functions by TAs（Therapeutic Areas）
OnGo (Fast) CMC: rapid, scalable and effective manufacturing
Oricell has generated proof-of-concept (POC) clinical data across multiple pipeline CAR-T products. Its lead program, Ori-C101, is an autologous GPC3-targeted CAR-T therapy for advanced hepatocellular carcinoma (HCC). Both a Phase I Investigator-Initiated Trial (IIT) and a Phase I IND study of Ori-C101 are completed. With far-leading-industry efficacy and safety profile, Ori-C101’s clinical data have been featured at major academic conferences such as ASCO (Free ASCO Whitepaper) 2021 and ASCO (Free ASCO Whitepaper) 2025. Ori-C101 is entering the registrational pivotal trial and is well positioned to become the world’s first approved CAR-T therapy for HCC.

Beyond Ori-C101, Oricell’s integrated platforms are also yielding multiple next-generation CAR-T products with multi-targets and multi-mechanism designs. The innovative secreting CAR-T, OriC902, has shown groundbreaking efficacy and durability in ultra-late-line and difficult-to-treat solid tumor patients. Additionally, the company has initiated an IIT study to evaluate its proprietary dual-targeted in vivo CAR-T.

"We are deeply grateful for the strong vote of confidence from our investors," said Dr. Helen Yang, Chairlady and CEO of Oricell Therapeutics. "Oricell will continue to push forward the global clinical advancement of our pipeline, as well as continuous R&D of in vivo products and new technologies. Leveraging our deep technical expertise, policy tailwind and expanding market opportunities, we are able to accelerate the development of our CAR-Ts in the clinic at full speed. Our mission is to bring efficacious and affordable cell therapies to cancer patients worldwide with the hope of cure. By doing that, we aim to become a leading global immunotherapy enterprise."

Mr. Peng Ren, Chairman and General Manager of Beijing Medical and Health Care Industry Investment Fund, noted: "We believe cell therapy is a pivotal frontier in the fight against solid tumors, and we are highly impressed by the clinical progress of Oricell’s GPC3 CAR-T in treating HCC. We strongly value the team’s R&D capabilities and commercial vision, and look forward to supporting the company in accelerating global clinical breakthroughs for its core products."

"As an early investor in Oricell, we’ve witnessed the Company’s evolution from a promising startup to a technology powerhouse—from advancing autologous CAR-Ts to secreting CAR-Ts, to pioneering a 3-day rapid manufacturing process, and now to exploring in vivo CAR-T in the clinic," said Mr. Xubo Hu, Managing Partner of Qiming Venture Partners. "Oricell’s relentless innovation efforts continue to impress us and we are delighted to back a team that is committed to building truly global and groundbreaking therapies."

(Press release, OriCell Therapeutics, JAN 12, 2026, View Source [SID1234661981])

On January 12, 2026 ARTBIO, Inc. ("ARTBIO"), a clinical-stage radiopharmaceutical company developing a new class of 212Pb alpha radioligand therapies (ARTs), reported dosing of two cohorts in the U.S. as part of its ARTISAN Phase 1 clinical trial of AB001, an ART being developed for the treatment of metastatic castration resistant prostate cancer (mCRPC). Patient cohorts include those with and without prior treatment with Lu177-PSMA targeted therapy.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The ARTBIO team is excited to continue to advance AB001 as our lead clinical asset for patients with and without prior Lu177-PSMA targeted therapy," said Margaret Yu, Chief Medical Officer of ARTBIO. "We are proud to collaborate with team members at BAMF Health and United Theranostics and are especially grateful to the patients who have enrolled in this study."

The ARTISAN clinical trial is being conducted across multiple clinical trial sites in the U.S. The company plans to expand the ARTISAN trial outside of the US in the second half of 2026.

"I’m proud to support prostate cancer patients by using United Theranostics infrastructure to bring access to the ARTISAN trial and to bring a new therapeutic option to patients," said Dr. Munir Ghesani, Chief Medical Officer at United Theranostics. "The ARTBIO team are passionate innovators who have constructed this trial with a strong patient-centric mindset."

BAMF Health Medical Director and principal investigator for the trial, Dr. Brandon Mancini, said, "AB001 PSMA-targeted radioligand therapy has the potential to reshape the treatment landscape for patients with metastatic castration-resistant prostate cancer who urgently need additional pathways forward."

About AB001
AB001 is an Alpha Radioligand Therapy (ART) consisting of a prostate-specific membrane antigen (PSMA)-targeted small molecule radiolabeled with 212Pb. PSMA is commonly overexpressed in mCRPC and has become an attractive target for imaging agents and therapies. It is the lead program for ARTBIO. In September 2025, an Investigational New Drug (IND) application for AB001 was cleared by The U.S. Food and Drug Administration (FDA). For more information about AB001 clinical trials, visit www.clinicaltrials.gov.

About the ARTISAN Study
ARTISAN is an open label, multi-center phase 1 study to investigate the safety, tolerability, pharmacokinetics, biodistribution and antitumor activity of the alpha radioligand therapy AB001 in patients with metastatic castration resistant prostate cancer (mCRPC).

(Press release, ARTBIO, JAN 12, 2026, View Source [SID1234661992])

On January 12, 2026 Erasca presented its corporate presentation.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

(Presentation, Erasca, JAN 12, 2026, View Source [SID1234661948])

On January 12, 2026 PTC Therapeutics, Inc. (NASDAQ: PTCT) reported an update on the Company’s progress and its outlook for 2026. Matthew B. Klein, M.D., Chief Executive Officer of PTC, will discuss these updates at the Company’s presentation at the J.P. Morgan 2026 Healthcare Conference on Monday, January 12, 2026, at 9:00 a.m. PST / 12:00 p.m. EST.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"2025 was a highly successful year for PTC, highlighted by the initial regulatory approvals of Sephience and strong start to the global launch," Dr. Klein said. "In 2026, we look forward to continuing the Sephience launch momentum, advancing our innovative earlier-stage programs and moving the company towards becoming cash flow breakeven."

Key Corporate Highlights

Unaudited 2025 product and royalty revenue of approximately $823.4 million, exceeding guidance, and unaudited 2025 product revenue of approximately $587.8 million
Unaudited Sephience Q4 2025 net revenue of approximately $92.5 million, including $81.6 million in the US and $10.9 million ex-US
Unaudited Sephience total net revenue of approximately $112.1 million in 2025 since launch
1,134 patient start forms received in the US as of December 31, 2025
946 total patients on commercial therapy worldwide as of December 31, 2025
Additional Sephience launches expected in 2026, including in Japan, Brazil and other geographies
In December 2025, PTC sold the remainder of its Evrysdi (risdiplam) royalty to Royalty Pharma for $240 million upfront and up to $60 million in sales-based milestones; PTC maintains the right to receive a $150 million milestone based on single-year Evrysdi sales of $2.5 billion by Roche
Cash, cash equivalents, and marketable securities of approximately $1.94 billion as of December 31, 2025
End-of-Phase 2 meeting with FDA held in Q4 2025 to discuss the votoplam Huntington’s disease (HD) program:
Alignment reached on design of global Phase 3 trial, planned to initiate in H1 2026
FDA confirmed openness to potential Accelerated Approval pathway given significant unmet need
Type C meeting with FDA held in December 2025 to discuss vatiquinone Friedreich’s ataxia program; FDA requested additional information from MOVE-FA Phase 3 trial prior to providing guidance on next steps
Translarna (ataluren) NDA remains under FDA review
Unaudited 2025 Financial Results

Total unaudited product and royalty revenue for full-year 2025 was approximately $823.4 million
Total unaudited product revenue for full-year 2025 was approximately $587.8 million
Sephience unaudited total net revenue for 2025 was approximately $112.1 million
DMD franchise unaudited revenue for full-year 2025 was approximately $381.8 million, including unaudited product revenue for Translarna of approximately $235.5 million and for Emflaza (deflazacort) of approximately $146.3 million
PTC expects to report approximately $235.7 million of full-year 2025 royalty revenue associated with Evrysdi
PTC is finalizing its financial results for the 2025 fiscal year. The above information is based on preliminary unaudited information and management estimates for the full year 2025, subject to the completion of PTC’s financial closing procedures. Evrysdi royalty revenue estimates are based on internal estimates and pending accounting treatment of Evrysdi royalty following the December 2025 transaction.

2026 Financial Guidance
For the full year 2026, PTC anticipates:

Total product revenue of $700 to $800 million, excluding Evrysdi royalty revenue and collaboration revenue
GAAP R&D and SG&A expense of $775 to $815 million
Non-GAAP R&D and SG&A expense of $680 to $720 million, excluding estimated non-cash, stock-based compensation expense of $95 million

(Press release, PTC Therapeutics, JAN 12, 2026, View Source [SID1234661966])

On January 12, 2026 Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256.HK) reported that the New Drug Application (NDA) for its novel, orally administered, highly selective, and potent small-molecule colony-stimulating factor 1 receptor (CSF-1R) inhibitor, pimicotinib (ABSK021), for the systemic treatment of patients with tenosynovial giant cell tumor (TGCT), has been formally accepted by the U.S. Food and Drug Administration (FDA).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Pimicotinib was independently developed by Abbisko Therapeutics and has been licensed to Merck KGaA, Darmstadt, Germany, for worldwide commercialization. In December 2025, pimicotinib was approved by the China National Medical Products Administration (NMPA) for the treatment of adult patients with symptomatic TGCT for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Additional applications are under review by regulatory bodies in other markets.

The FDA’s acceptance of the NDA for pimicotinib is supported by the robust efficacy and safety outcomes from the global, multicenter, randomized, double-blind, placebo-controlled Phase III MANEUVER trial. In the trial, TGCT patients who received once-daily oral pimicotinib achieved a statistically significant improvement in the primary endpoint of objective response rate (ORR) evaluated at Week 25 by blinded independent review committee (BIRC) based on RECIST v1.1.

The trial also demonstrated statistically significant and clinically meaningful improvements in all secondary endpoints related to key patient-reported outcomes in TGCT, including improvements in active range of motion and physical function and reductions in stiffness and pain.

Longer-term results with a median follow-up of 14.3 months further showed ORR continued to increase over time among patients treated with pimicotinib from the beginning of the study.

TGCT is a rare, locally aggressive tumor occurring in or around the joint leading to progressive swelling, stiffness and reduced mobility of the affected joint, significantly impacting daily activities and quality of life. If left untreated or in recurrent cases, TGCT may result in irreversible damage to the bone, joint and surrounding tissues. With regulatory submissions progressing across major markets worldwide, pimicotinib is expected to provide TGCT patients with a once-daily, oral, effective and well-tolerated therapeutic option, helping address unmet clinical needs in the management of TGCT.

About Pimicotinib

Pimicotinib is a novel, oral, highly selective, and potent small-molecule CSF-1R inhibitor independently developed by Abbisko Therapeutics. Positive results from the global Phase III MANEUVER study of pimicotinib for the treatment of Tenosynovial Giant Cell Tumor (TGCT) were announced in November 2024. Currently, pimicotinib has been approved by the National Medical Products Administration (NMPA) in China for the treatment of adult patients with symptomatic TGCT for which surgical resection will potentially cause functional limitation or relatively severe morbidity. In December 2023, Abbisko entered into an agreement with Merck KGaA, Darmstadt, Germany, pertaining to the commercial rights to pimicotinib, pursuant to which Merck KGaA, Darmstadt, Germany, is responsible for the commercialization of pimicotinib globally.

Outside of China, pimicotinib has been granted Breakthrough Therapy Designation by the US Food and Drug Administration (FDA) and PRIME Designation by the European Medicines Agency (EMA).

(Press release, Abbisko Therapeutics, JAN 12, 2026, View Source [SID1234661982])